Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes T. Forst et al. Linagliptin added to metformin in Type 2 diabetes.
Autor: | Forst, T., Uhlig-Laske, B., Ring, A., Graefe-Mody, U., Friedrich, C., Herbach, K., Woerle, H.-J., Dugi, K. A. |
---|---|
Předmět: |
ANALYSIS of covariance
ANALYSIS of variance COMBINATION drug therapy STATISTICAL correlation DRUG resistance ENZYME inhibitors GLYCOSYLATED hemoglobin HYPOGLYCEMIC agents MEDICAL cooperation TYPE 2 diabetes HEALTH outcome assessment REGRESSION analysis RESEARCH STATISTICAL sampling TREATMENT effectiveness BLIND experiment METFORMIN BLOOD DRUG administration DRUG dosage DRUG side effects PHARMACOKINETICS DRUG therapy |
Zdroj: | Diabetic Medicine; Dec2010, Vol. 27 Issue 12, p1409-1419, 11p, 1 Diagram, 4 Charts, 3 Graphs |
Abstrakt: | Aims The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, linagliptin, added to ongoing metformin therapy, were assessed in patients with Type 2 diabeteswho had inadequate glycaemic control (HbA |
Databáze: | Complementary Index |
Externí odkaz: |